View Filing Data

Document and Entity Information - shares	6 Months Ended
Jun. 30, 2018	Aug. 07, 2018
Entity Registrant Name	Avista Healthcare Public Acquisition Corp.
Entity Central Index Key	0001661181
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Class A
Entity Common Stock, Shares Outstanding		31,000,000
Class B
Entity Common Stock, Shares Outstanding		7,750,000

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash	$ 64,411	$ 125,886
Prepaid expenses	96,055	168,553
Total current assets	160,466	294,439
Cash and cash equivalents held in Trust Account	314,820,605	312,497,921
Total assets	314,981,071	312,792,360
Current liabilities
Note payable to Sponsor	475,000	100,000
Accrued expenses	5,421,098	3,828,722
Total current liabilities	5,896,098	3,928,722
Deferred underwriting commission	10,850,000	10,850,000
Total liabilities	16,746,098	14,778,722
COMMITMENTS
Class A ordinary shares subject to possible redemption, $0.0001 par value; 28,874,489 and 29,067,145 shares at conversion value at June 30, 2018 and December 31, 2017	293,234,970	293,013,630
Shareholders' equity
Preferred shares, $0.0001 par value, 1,000,000 shares authorized: no shares issued and outstanding at June 30, 2018 and December 31, 2017
Additional paid-in capital	7,105,453	7,326,813
Accumulated deficit	(2,106,438)	(2,327,773)
Total shareholders' equity	5,000,003	5,000,008
Total liabilities and shareholders' equity	314,981,071	312,792,360
Class A
Shareholders' equity
Ordinary shares, value	213	193
Class B
Shareholders' equity
Ordinary shares, value	$ 775	$ 775

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Class A ordinary shares subject to possible redemption, par value	$ 0.0001	$ 0.0001
Class A ordinary shares subject to possible redemption, shares issued	28,874,489	29,067,145
Preferred shares, par value (in dollar per share)	$ 0.0001	$ 0.0001
Preferred shares, shares authorized	1,000,000	1,000,000
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0
Ordinary shares, par value (in dollar per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	220,000,000	220,000,000
Class A
Ordinary shares, par value (in dollar per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	200,000,000	200,000,000
Ordinary shares, shares issued	2,125,511	1,932,855
Ordinary shares, shares outstanding	2,125,511	1,932,855
Ordinary shares subject to possible redemption	28,874,489	29,067,145
Class B
Ordinary shares, par value (in dollar per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	20,000,000	20,000,000
Ordinary shares, shares issued	7,750,000	7,750,000
Ordinary shares, shares outstanding	7,750,000	7,750,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income	$ 221,335	$ 521,197
Adjustments to reconcile net income to net cash used in operating activities:
Interest/dividend income received in the Trust Account	(2,322,684)	(375,000)
Change in operating assets and liabilities:
Accrued interest receivable held in Trust Account		(586,653)
Prepaid expenses	72,498	79,381
Accrued expenses	1,592,376	35,043
Net cash used in operating activities	(436,475)	(326,032)
Cash flows from financing activities:
Proceeds from note payable to Sponsor	375,000
Payment of offering costs		(427,578)
Net cash provided by/(used) in financing activities	375,000	(427,578)
Net change in cash	(61,475)	(753,610)
Cash at beginning of period	125,886	1,040,068
Cash at end of period	64,411	286,458
Supplemental disclosure of non-cash financing activities:
Change in ordinary shares subject to possible redemption	$ 221,340	$ 521,190

Organization and Plan of Business Operations	6 Months Ended
Organization and Plan of Business Operations	Jun. 30, 2018
Organization and Plan of Business Operations
Organization and Plan of Business Operations	Note 1—Organization and Plan of Business Operations Organization and General Avista Healthcare Public Acquisition Corp. (the “Company”) was incorporated as a Cayman Islands exempted company on December 4, 2015. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “business combination”). The Company has focused and will continue to focus its search for a target business in the healthcare industry, although it may seek to complete a business combination with an operating company in any industry or sector. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (as amended, the “JOBS Act”). The Company’s sponsor is Avista Acquisition Corp. (the “Sponsor”), which was incorporated on December 4, 2015. At June 30, 2018, the Company had not commenced any operations. All activity through June 30, 2018 relates to the Company’s formation, its initial public offering of 30,000,000 units (the “Units”) at $10.00 per Unit, each consisting of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Shares”), and one warrant (the “Warrants”) to purchase one-half of one Class A Share (the “Public Offering”) and efforts directed towards locating a suitable initial business combination. The Company also granted the Underwriters (as defined below) of the Public Offering a 45-day option to purchase up to 4,500,000 additional Units to cover over-allotments (the “Over-allotment Option”). The Class A Shares sold as part of the Units in the Public Offering are sometimes referred to herein as the “public shares.” The Company will not generate any operating revenues until after completion of a business combination, at the earliest. Financing The registration statement for the Company’s Public Offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 7, 2016. The Public Offering closed on October 14, 2016 (the “Close Date”). The Sponsor and certain other accredited investors (the “Initial Shareholders”) purchased an aggregate of 16,000,000 warrants (the “Private Placement Warrants”) at a purchase price of $0.50 per warrant, or $8,000,000 in the aggregate, in a private placement at the Close Date (the “Private Placement”). On November 28, 2016, the Company consummated the closing of the sale of 1,000,000 Units which were sold pursuant to the Over-allotment Option. The Company also consummated a simultaneous private placement of an additional 400,000 Private Placement Warrants with the Initial Shareholders. Following the closing of the Over-allotment Option and Private Placement, an additional $10,000,000 was placed into the Trust Account (defined below), after paying additional underwriting discounts of $200,000. The Company intends to finance a business combination with net proceeds from its $310,000,000 Public Offering and $8,200,000 Private Placement (see Note 3). Following the Public Offering, after paying underwriting discounts of $6,200,000 and funds designated for operational use of $2,000,000, the remaining net proceeds of $310,000,000 were deposited in a trust account with Continental Stock Transfer and Trust Company acting as trustee (the “Trust Account”) as described below. The Trust Account As of January 1, 2018 the funds in the Trust Account were invested in a qualified Money Market Fund within the meaning of section 2(a)(16) of the Investment Company Act of 1940. On March 8, 2018 the funds in the Trust Account were invested in U.S. government treasury bills, which matured on April 5, 2018. On April 5, 2018 the funds in the Trust Account were reinvested in U.S. government treasury bills, which matured on May 3, 2018. On May 3, 2018, the funds in the Trust Account were reinvested in US government treasury bills, which matured on May 31, 2018. On May 31, 2018, the funds in the Trust Account were reinvested in US government treasury bills, which matured on June 28, 2018. On June 28, 2018 the funds in the Trust Account were invested in a qualified Money Market Fund within the meaning of section 2(a)(16) of the Investment Company Act of 1940. The funds in the Trust Account will continue to be invested in U.S. government treasury bills, or other similar investments until the earlier of (i) the consummation of the business combination and (ii) the Company’s failure to consummate a business combination within the prescribed time. Placing funds in the Trust Account may not protect those funds from third-party claims against the Company. Although the Company will seek to have all vendors, service providers (other than its independent auditors), prospective target businesses or other entities it engages execute agreements with the Company waiving any claim of any kind in or to any monies held in the Trust Account, there is no guarantee that such persons will execute such agreements. The Sponsor has agreed that it will be liable to the Company under certain circumstances if and to the extent any claims by such persons reduce the amount of funds in the Trust Account below a specified threshold. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor’s only assets are securities of the Company. Therefore, the Sponsor may not be able to satisfy those obligations should they arise. The remaining net proceeds (not held in the Trust Account) may be used to pay for business, legal and accounting due diligence on prospective acquisitions and continuing general and administrative expenses as well as any taxes. The balance in the Trust Account as of June 30, 2018 was $314,820,605. Business Combination The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, the sale of the Private Placement Warrants and the Over-allotment Option, although substantially all of the net proceeds are intended to be applied generally toward consummating a business combination. There is no assurance that the Company will be able to successfully effect a business combination. The Company will provide the holders of the public shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their public shares upon the completion of the business combination, either (i) in connection with a shareholder meeting called to approve the business combination or (ii) by means of a tender offer, in either case at a per‑share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the business combination, including interest (which interest shall be net of taxes payable) divided by the number of then outstanding public shares. Notwithstanding the foregoing, if the Company seeks shareholder approval of the business combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the public shares. In connection with any shareholder vote required to approve any business combination, the Initial Shareholders have agreed (i) to vote any of their respective Ordinary Shares (as defined below) in favor of the business combination and (ii) not to redeem any of their Ordinary Shares in connection therewith. The NASDAQ rules require that the business combination must be with one or more target businesses that together have an aggregate fair market value equal to at least 80% of the balance in the Trust Account (less any Deferred Commissions (as defined below) and taxes payable on interest earned) at the time of the Company signing a definitive agreement in connection with the business combination. If the Company has not completed a business combination by October 14, 2018, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per‑share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable, and less up to $50,000 of interest to pay dissolution expenses) divided by the number of then outstanding public shares, which redemption will completely extinguish the rights of the Public Shareholders as Shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its Board of Directors, dissolve and liquidate, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. In the event of a liquidation, the Public Shareholders will be entitled to receive a full pro rata interest in the Trust Account (initially anticipated to be approximately $10.00 per share, plus any pro rata interest earned on the Trust Account not previously released to the Company and less up to $50,000 of interest to pay dissolution expenses). There will be no redemption rights or liquidating distributions with respect to the Founder Shares (as defined below) or the Private Placement Warrants, which will expire worthless if the Company fails to complete a business combination within the 24‑month time period. Previously Proposed Business Combination On August 21, 2017, the Company, Avista Healthcare Merger Sub, Inc. (“Merger Sub”), Avista Healthcare NewCo, LLC (“NewCo”), Envigo International Holdings, Inc. (“Envigo”), and Jermyn Street Associates, LLC, solely in its capacity as Shareholder Representative, entered into a Transaction Agreement (as amended on November 22, 2017 and as further amended on December 22, 2017, January 21, 2018 and February 9, 2018, (the “Transaction Agreement”), which provided for a proposed business combination between the Company and Envigo. Termination On February 14, 2018, the Company and Envigo entered into the Mutual Termination Agreement pursuant to Section 7.1(a) of the Transaction Agreement, pursuant to which the Transaction Agreement was terminated effective as of February 14, 2018. The Company intends to continue to pursue a business combination. Liquidity As of June 30, 2018, the Company had a working capital deficit of $5,735,632. In order to preserve liquidity, as of April 30, 2017, the affiliate of the Sponsor (the “Affiliate”) has agreed to defer payment of the monthly administrative fee under the Administrative Services Agreement until the initial business combination, at which time all such accrued but unpaid fees will be paid to the Affiliate. In addition certain vendors have agreed to defer the payment of invoices until the earlier of a close of a business combination or a liquidation of the Company. As of June 30, 2018, $5,387,178 of accrued expenses were deferred. The Company issued to the Sponsor on August 11, 2017, as amended and restated on May 3, 2018, an unsecured promissory note pursuant to which the Company is permitted to borrow up to $600,000 in aggregate principal amount. As of June 30, 2018, the Company has borrowed $475,000 under such note. This note is non-interest bearing and payable on the earlier of October 14, 2018 or the closing of a proposed business combination. Based on the foregoing, management believes that the Company will have sufficient working capital to continue as a going concern until the earlier of October 14, 2018 or the close of a business combination.

Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Significant Accounting Policies

Significant Accounting Policies

Note 2—Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in U.S dollars in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all of the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s form 10-K, as filed with the SEC on March 14, 2018. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other future period.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. Merger Sub and NewCo are both 100% owned by the Company and are included as part of the unaudited consolidated financial statements.

Emerging Growth Company

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, approximates the carrying amounts represented in the balance sheet.

Fair Value Measurement

ASC 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of investment, characteristics specific to the investment, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I measurements) and the lowest priority to unobservable inputs (Level III measurements).

Investments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value.

The three levels of the fair value hierarchy under ASC 820 are as follows:

Level I – Quoted prices (unadjusted) in active markets for identical investments at the measurement date are used.

Level II – Pricing inputs are other than quoted prices included within Level I that are observable for the investment, either directly or indirectly. Level II pricing inputs include quoted prices for similar investments in active markets, quoted prices for identical or similar investments in markets that are not active, inputs other than quoted prices that are observable for the investment, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level III – Pricing inputs are unobservable and include situations where there is little, if any, market activity for the investment. The inputs used in determination of fair value require significant judgment and estimation.

In some cases, the inputs used to measure fair value might fall within different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the investment is categorized in its entirety is determined based on the lowest level input that is significant to the investment. Assessing the significance of a particular input to the valuation of an investment in its entirety requires judgment and considers factors specific to the investment. The categorization of an investment within the hierarchy is based upon the pricing transparency of the investment and does not necessarily correspond to the perceived risk of that investment.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2018 and December 31, 2017.


Description	June 30, 2018		Level 1		Level 2		Level 3
Investments and cash held in Trust Account	$	314,820,605	$	314,820,605	$	—	$	—
Total	$	314,820,605	$	314,820,605	$	—	$	—

Description	December 31, 2017		Level 1		Level 2		Level 3
Investments and cash held in Trust Account	$	312,497,921	$	312,497,921	$	—	$	—
Total	$	312,497,921	$	312,497,921	$	—	$	—

Net Income (Loss) Per Share

The Company complies with accounting and disclosure requirements ASC Topic 260, “Earnings Per Share.” Net income/(loss) per ordinary share is computed by dividing net income/(loss) attributable to ordinary shares by the weighted average number of ordinary shares outstanding for the period. Ordinary shares subject to possible redemption at June 30, 2018 and 2017, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic income (loss) per share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. Also excluded, to the extent dilutive, is the incremental number of Class A Shares to settle the Private Placement Warrants and the Warrants included in the Units. At June 30, 2018 and 2017, the Company had outstanding warrants for the purchase of up to 23,700,000 Class A Shares. For the period ended June 30, 2018 and 2017, the weighted average of these shares was excluded from the calculation of diluted net income/(loss) per ordinary share since the exercise of the warrants is contingent on the occurrence of future events. As a result, diluted net income/(loss) per ordinary share is equal to basic net income/(loss) per ordinary share.

Reconciliation Of Net Income (Loss) Per Share

The Company’s net loss is adjusted for the portion of income that is attributable to ordinary shares subject to redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted loss per ordinary share is calculated as follows:


	Three Months		Three Months		Six Months		Six Months
	Ended		Ended		Ended		Ended
	June 30, 2018		June 30, 2017		June 30, 2018		June 30, 2017

Net income	$	356,988	$	380,334	$	221,335	$	521,197
Less: Income attributable to ordinary shares subject to redemption		(1,210,414)		(572,452)		(2,163,429)		(914,236)
Adjusted net loss	$	(853,426)	$	(192,118)	$	(1,942,094)	$	(393,039)

Weighted average shares outstanding, basic and diluted		9,792,054		9,259,571		9,738,355		9,249,575

Basic and diluted net loss per ordinary share	$	(0.09)	$	(0.02)	$	(0.20)	$	(0.04)

Income Taxes

The Company accounts for income taxes under FASB ASC 740, Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more‑likely‑than‑not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits as of June 30, 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

There is currently no taxation imposed on income by the Government of the Cayman Islands.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

Subsequent Events

Management has performed an evaluation of subsequent events from June 30, 2018 through the date which these condensed consolidated financial statements were issued. Based upon the review, management did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2018
Related Party Transactions
Related Party Transactions	Note 6—Related Party Transactions Related Party Loans The Company issued to the Sponsor on December 14, 2015, as amended and restated on September 1, 2016, an unsecured promissory note pursuant to which the Company was permitted to borrow up to $300,000 in aggregate principal amount. Between inception and the Close Date, the Company borrowed $300,000. This note was non-interest bearing and was repaid in full to the Sponsor at the Close Date. The Company issued to the Sponsor on August 11, 2017, as amended and restated on May 3, 2018, an unsecured promissory note pursuant to which the Company is permitted to borrow up to $600,000 in aggregate principal amount. As of June 30, 2018, the Company has borrowed $475,000 under such note. This note is non-interest bearing and payable on the earlier of October 14, 2018 or the closing of the business combination. The Sponsor may make a working capital loan to the Company and up to $1,500,000 of such loan may be converted into warrants, at the price of $0.50 per warrant at the option of the Sponsor. Such warrants would be identical to the Private Placement Warrants. Administrative Services Agreement The Company presently occupies office space provided by an Affiliate. The Affiliate has agreed that, until the Company consummates a business combination, it will make such office space, as well as certain support services, available to the Company, as may be required by the Company from time to time. The Company will pay the Affiliate an aggregate of $10,000 per month for such office space and support services. As of April 30, 2017, the Affiliate has agreed to defer payment of the monthly administrative fee under the Administrative Services Agreement until the initial business combination, at which time all such accrued but unpaid fees will be paid to the Affiliate. As of June 30, 2018, $140,000 is accrued and included in accrued expenses. Private Placement Warrants The Initial Shareholders purchased 16,000,000 Private Placement Warrants at $0.50 per warrant (for an aggregate purchase price of $8,000,000) from the Company in a Private Placement on the Close Date. A portion of the proceeds from the sale of the Private Placement Warrants were placed into the Trust Account. The Initial Shareholders have also purchased an additional 400,000 Private Placement Warrants at $0.50 per warrant (for an aggregate purchase price of $200,000) simultaneously with the underwriter’s exercise of the Over-Allotment Option. Each Private Placement Warrant is exercisable for one‑half of one Class A Share. Two Private Placement Warrants must be exercised for one whole Class A Share at a price of $11.50 per share. The Private Placement Warrants are identical to the Warrants included in the Units to be sold in the Public Offering except that the Private Placement Warrants: (i) will not be redeemable by the Company and (ii) may be exercised for cash or on a cashless basis, as described in the registration statement relating to the Public Offering, so long as they are held by the Initial Shareholders or any of their permitted transferees. Additionally, the Initial Shareholders have agreed not to transfer, assign or sell any of the Private Placement Warrants, including the Class A Shares issuable upon exercise of the Private Placement Warrants (except to certain permitted transferees), until 30 days after the completion of the business combination. Founder Shares In connection with the organization of the Company, on December 14, 2015, an aggregate of 8,625,000 Class B Shares (the “Founder Shares”) were sold to the Sponsor at a price of approximately $0.003 per share, for an aggregate price of $25,000. In October 2016, the Sponsor transferred 50,000 Founder Shares to each of the Company’s independent directors at a price per share of approximately $0.003 per share. In addition, at such time, each of our independent directors purchased an additional 421,250 Founder Shares from our Sponsor at a price per share of approximately $0.003 per share. The 8,625,000 Founder Shares included an aggregate of up to 1,125,000 shares that were subject to forfeiture if the Over‑allotment Option was not exercised in full by the Underwriters in order to maintain the Initial Shareholders’ ownership at 20% of the issued and outstanding Ordinary Shares upon completion of the Public Offering. Following the partial exercise of the Over-allotment Option, 875,000 Founder Shares were forfeited in order to maintain the Initial Shareholder’s ownership at 20% of the issued and outstanding Ordinary Shares. On November 28, 2016, our Sponsor sold 161,180 Founder Shares and 350,114 Private Placement Warrants to one of our independent directors at their original purchase price. On July 5, 2017, our Sponsor sold 186,320 Founder Shares and 404,723 Private Placement Warrants to one of our independent directors at their original per share purchase price. The Founder Shares are identical to the Class A Shares included in the Units sold in the Public Offering, except that the Founder Shares (i) have the voting rights described in Note 7, (ii) are subject to certain transfer restrictions described below, and (iii) are convertible into Class A Shares on a one‑for‑one basis, subject to adjustment pursuant to the anti‑dilution provisions contained therein. The Founder Shares may not be transferred, assigned or sold until the earlier of (i) one year after the completion of the business combination and (ii) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction after the business combination that results in all of the Public Shareholders having the right to exchange their Class A Shares for cash, securities or other property. Notwithstanding the foregoing, if the last sale price of the Class A Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 trading day period commencing at least 150 days after the business combination, the Founder Shares will be released from the lock‑up.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Emerging Growth Company

Use of Estimates

Cash and Cash Equivalents

Concentration of Credit Risk

Financial Instruments

Fair Value Measurement

The three levels of the fair value hierarchy under ASC 820 are as follows:

Level I – Quoted prices (unadjusted) in active markets for identical investments at the measurement date are used.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2018 and December 31, 2017.


Description	June 30, 2018		Level 1		Level 2		Level 3
Investments and cash held in Trust Account	$	314,820,605	$	314,820,605	$	—	$	—
Total	$	314,820,605	$	314,820,605	$	—	$	—

Description	December 31, 2017		Level 1		Level 2		Level 3
Investments and cash held in Trust Account	$	312,497,921	$	312,497,921	$	—	$	—
Total	$	312,497,921	$	312,497,921	$	—	$	—

Net Income (Loss) Per Share

Reconciliation Of Net Income (Loss) Per Share


	Three Months		Three Months		Six Months		Six Months
	Ended		Ended		Ended		Ended
	June 30, 2018		June 30, 2017		June 30, 2018		June 30, 2017

Net income	$	356,988	$	380,334	$	221,335	$	521,197
Less: Income attributable to ordinary shares subject to redemption		(1,210,414)		(572,452)		(2,163,429)		(914,236)
Adjusted net loss	$	(853,426)	$	(192,118)	$	(1,942,094)	$	(393,039)

Weighted average shares outstanding, basic and diluted		9,792,054		9,259,571		9,738,355		9,249,575

Basic and diluted net loss per ordinary share	$	(0.09)	$	(0.02)	$	(0.20)	$	(0.04)

Income Taxes

There is currently no taxation imposed on income by the Government of the Cayman Islands.

Recent Accounting Standards

Subsequent Events

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Significant Accounting Policies

Schedule of fair value of assets

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2018 and December 31, 2017.


Description	June 30, 2018		Level 1		Level 2		Level 3
Investments and cash held in Trust Account	$	314,820,605	$	314,820,605	$	—	$	—
Total	$	314,820,605	$	314,820,605	$	—	$	—

Description	December 31, 2017		Level 1		Level 2		Level 3
Investments and cash held in Trust Account	$	312,497,921	$	312,497,921	$	—	$	—
Total	$	312,497,921	$	312,497,921	$	—	$	—

Schedule on net income (loss) per share


	Three Months		Three Months		Six Months		Six Months
	Ended		Ended		Ended		Ended
	June 30, 2018		June 30, 2017		June 30, 2018		June 30, 2017

Net income	$	356,988	$	380,334	$	221,335	$	521,197
Less: Income attributable to ordinary shares subject to redemption		(1,210,414)		(572,452)		(2,163,429)		(914,236)
Adjusted net loss	$	(853,426)	$	(192,118)	$	(1,942,094)	$	(393,039)

Weighted average shares outstanding, basic and diluted		9,792,054		9,259,571		9,738,355		9,249,575

Basic and diluted net loss per ordinary share	$	(0.09)	$	(0.02)	$	(0.20)	$	(0.04)

Organization and Plan of Business Operations - Business Combination and Liquidity (Details)	6 Months Ended
	Jun. 30, 2018 USD ($) item $ / shares	May 03, 2018 USD ($)	Dec. 31, 2017 USD ($)
Business Combination
Business combination, redemption valuation period prior to consummation	2 days
Uncompleted business combination, wind-up period	10 days
Liquidity
Working capital deficit	$ 5,735,632
Deferred accrued expenses	5,387,178
Note payable to Sponsor	$ 475,000		$ 100,000
Promissory note amount		$ 600,000
Minimum
Business Combination
Number of target businesses for Business Combination \| item	1
Class A \| Maximum
Business Combination
Percent of aggregate public shares that may be redeemed by a shareholder	15.00%
Assets held in trust
Business Combination
Price of units (in dollars per unit) \| $ / shares	$ 10.00
Assets held in trust \| Maximum
Business Combination
Portion of interest income allowed to pay dissolution expenses	$ 50,000
Assets held in trust \| Minimum
Business Combination
Business combination, fair value percent of assets held in trust	80.00%

Significant Accounting Policies (Details) - USD ($)		3 Months Ended		6 Months Ended
Significant Accounting Policies (Details) - USD ($)	Oct. 14, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	May 03, 2018	Dec. 31, 2017
Principles of Consolidation
Ownership percentage				100.00%
Concentration of Credit Risk
Federal depository insurance coverage		$ 250,000		$ 250,000
Fair Value Measurement
Investment and cash held in Trust Account		314,820,605		314,820,605			$ 312,497,921
Total		314,820,605		314,820,605			312,497,921
Net Income (Loss) Per Share
Net income		356,988	$ 380,334	221,335	$ 521,197
Less: Income attributable to ordinary shares subject to redemption		(1,210,414)	(572,452)	(2,163,429)	(914,236)
Adjusted net income		$ (853,426)	$ (192,118)	$ (1,942,094)	$ (393,039)
Weighted average shares outstanding, basic and diluted		9,792,054	9,259,571	9,738,355	9,249,575
Basic and diluted net loss per ordinary share		$ (0.09)	$ (0.02)	$ (0.20)	$ (0.04)
Income Taxes
Unrecognized tax benefits		$ 0		$ 0
Subsequent events
Promissory note amount						$ 600,000
Fair Value, Inputs, Level 1
Fair Value Measurement
Investment and cash held in Trust Account		314,820,605		314,820,605			312,497,921
Total		$ 314,820,605		$ 314,820,605			$ 312,497,921
Class A
Net Income (Loss) Per Share
Outstanding warrants to purchase Class A Shares				23,700,000
IPO
Offering Costs
Underwriting discounts	$ 6,200,000

Public Offering (Details) - $ / shares			6 Months Ended
Public Offering (Details) - $ / shares	Nov. 28, 2016	Oct. 14, 2016	Jun. 30, 2018
Public Offering
Period after the completion of the Business Combination for exercise of warrants (in days)		30 days
Expiration period of warrants after completion of the Business Combination		5 years
Redemption price per warrant		$ 0.01
Redemption notice period		30 days
Warrants redemption covenant, threshold trading days		20 days
Warrants redemption covenant, threshold consecutive trading days		30 days
Class A
Public Offering
Number of warrants required for conversion to one whole share		2
Exercise price		$ 11.50
Minimum price per share required for redemption of warrants		$ 24.00
IPO
Public Offering
Sale of units		310,000,000	30,000,000
Price of units (in dollars per unit)		$ 10.00	$ 10.00
Number of warrants included in each unit		1	1
IPO \| Class A
Public Offering
Number of shares of common stock included in each unit		1	1
Number of shares called by each warrant		0.5	0.5
Over-Allotment Option
Public Offering
Sale of units	1,000,000
IPO and Over-Allotment Option
Public Offering
Sale of units		31,000,000

Related Party Transactions - Related Party Loans and Administrative Services Agreement (Details) - USD ($)		10 Months Ended
	Oct. 14, 2016	Oct. 14, 2016	Jun. 30, 2018	May 03, 2018	Dec. 31, 2017	Dec. 14, 2015
Related Party Transactions
Promissory note amount				$ 600,000
Note payable to Sponsor			$ 475,000		$ 100,000
Accrued expenses			$ 5,421,098		$ 3,828,722
Related Party Loans \| Sponsor \| Unsecured Promissory Note
Related Party Transactions
Promissory note, maximum borrowing capacity						$ 300,000
Amount borrowed between inception and the Close Date		$ 300,000
Repayment of note payable to Sponsor	$ (300,000)
Related Party Loans \| Sponsor \| Working Capital Loan
Related Party Transactions
Conversion price per warrant			$ 0.50
Related Party Loans \| Sponsor \| Working Capital Loan \| Maximum
Related Party Transactions
Portion of working capital loan that may be converted into warrants			$ 1,500,000
Administrative Services Agreement
Related Party Transactions
Monthly payment for office space and support services			10,000
Accrued expenses			$ 140,000

Related Party Transactions - Founder Shares (Details)				1 Months Ended	6 Months Ended	12 Months Ended
Related Party Transactions - Founder Shares (Details)	Jul. 05, 2017 shares	Nov. 28, 2016 shares	Dec. 14, 2015 USD ($) $ / shares shares	Oct. 31, 2016 $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) shares	Oct. 14, 2016
Related Party Transactions
Minimum ownership of ordinary shares by initial shareholders (as a percent)					20.00%	20.00%
Founder Shares redemption covenant, minimum price per share \| $ / shares					$ 12.00
Class B
Related Party Transactions
Ordinary shares, shares issued					7,750,000	7,750,000
Ordinary shares, value \| $					$ 775	$ 775
Ratio of conversion from Class B to Class A ordinary shares					1	1
Founder Shares Transactions \| Class B
Related Party Transactions
Ratio of conversion from Class B to Class A ordinary shares					1
Restriction to transfer Class B ordinary shares (in years)					1 year
Founder Shares redemption covenant, threshold trading days					20 days
Founder Shares redemption covenant, threshold consecutive trading days					30 days
Founder Shares redemption covenant, minimum restriction term (in days)					150 days
Founder Shares Transactions \| Sponsor
Related Party Transactions
Shares subject to forfeiture			1,125,000
Founder Shares Transactions \| Sponsor \| Class B
Related Party Transactions
Ordinary shares, shares issued			8,625,000
Price per share \| $ / shares			$ 0.003
Ordinary shares, value \| $			$ 25,000
Shares forfeited		875,000
Share sold	186,320	161,180
Founder Shares Transactions \| Initial Shareholders
Related Party Transactions
Minimum ownership of ordinary shares by initial shareholders (as a percent)			20.00%				20.00%
Founder Shares Transactions \| Director \| Class B
Related Party Transactions
Ordinary shares, shares issued				50,000
Price per share \| $ / shares				$ 0.003
Additional purchase of ordinary shares				421,250
Private Placement Warrants \| Sponsor \| Class B
Related Party Transactions
Share sold	404,723	350,114

Shareholders' Equity (Details)	6 Months Ended	12 Months Ended
Shareholders' Equity (Details)	Jun. 30, 2018 USD ($) $ / shares shares	Dec. 31, 2017 $ / shares shares
Shareholders' Equity
Preferred shares, shares authorized	1,000,000	1,000,000
Preferred shares, par value (in dollar per share) \| $ / shares	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0
Ordinary shares, shares authorized	220,000,000	220,000,000
Ordinary shares, par value (in dollar per share) \| $ / shares	$ 0.0001	$ 0.0001
Ordinary shares, voting rights per share	one	one
Minimum ownership of ordinary shares by initial shareholders (as a percent)	20.00%	20.00%
Ordinary shares subject to redemption, shares issued	28,874,489	29,067,145
Ordinary shares subject to redemption, shares outstanding	28,874,489	29,067,145
Net tangible assets \| $	$ 5,000,001
Class A
Shareholders' Equity
Ordinary shares, shares authorized	200,000,000	200,000,000
Ordinary shares, par value (in dollar per share) \| $ / shares	$ 0.0001	$ 0.0001
Total ordinary shares issued, including shares subject to redemption	31,000,000	31,000,000
Total ordinary shares outstanding, including shares subject to redemption	31,000,000	31,000,000
Ordinary shares, shares issued	2,125,511	1,932,855
Ordinary shares, shares outstanding	2,125,511	1,932,855
Class B
Shareholders' Equity
Ordinary shares, shares authorized	20,000,000	20,000,000
Ordinary shares, par value (in dollar per share) \| $ / shares	$ 0.0001	$ 0.0001
Ratio of conversion from Class B to Class A ordinary shares	1	1
Ordinary shares, shares issued	7,750,000	7,750,000
Ordinary shares, shares outstanding	7,750,000	7,750,000

Commitments	6 Months Ended
Commitments	Jun. 30, 2018
Commitments
Commitments	Note 4—Commitments Underwriting Agreement The Company entered into an agreement with the underwriters (the “Underwriters”) of the Public Offering (“Underwriting Agreement”) that required the Company to pay an underwriting discount of 2.0% of the gross proceeds of the Public Offering and Over-allotment Option to the Underwriters at the Close Date of the Public Offering. The Company will pay the Underwriters a deferred underwriting discount of 3.5% of the gross proceeds of the Public Offering and Over-allotment Option (“Deferred Commissions”) at the time of the closing of the business combination. The Deferred Commission will be placed in the Trust Account and will be forfeited if the Company is unable to complete a business combination in the prescribed time. Registration Rights Holders of the Founder Shares, the Private Placement Warrants, and warrants that may be issued on conversion of working capital loans (and any Class A Shares issuable upon exercise of such warrants and upon conversion of the Founder Shares) will be entitled to registration rights with respect to such securities (in the case of the Founder Shares, only after conversion to Class A Shares) pursuant to an agreement signed on the effective date of the Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities for resale. In addition, the holders have certain “piggy‑back” registration rights with respect to registration statements filed subsequent to the business combination. However, the registration rights agreement will provide that the Company will not permit any registration statement to become effective until termination of applicable lock‑up periods with respect to such securities.

Cash Held in Trust Account	6 Months Ended
Cash Held in Trust Account	Jun. 30, 2018
Cash Held in Trust Account
Cash Held in Trust Account	Note 5—Cash Held in Trust Account Gross proceeds of $310,000,000 and $8,200,000 from the Public Offering and Over-allotment Option, and Private Placement, respectively, less underwriting discounts of $6,200,000 and $2,000,000 designated for offering expenses and to fund the Company’s ongoing administrative and acquisition search costs, were held in the Trust Account at the Close Date.

Organization and Plan of Business Operations - Financing (Details) - USD ($)			6 Months Ended
	Nov. 28, 2016	Oct. 14, 2016	Jun. 30, 2018
Private Placement
Organization and Financing
Warrants issued (in shares)	400,000	16,000,000
Purchase price of warrants		$ 0.50
Aggregate value of warrants, net of proceeds reserved for operations		$ 8,000,000
Aggregate value of warrants		$ 8,200,000
IPO
Organization and Financing
Sale of units		310,000,000	30,000,000
Net proceeds from sale of units		$ 310,000,000
Payment of underwriting discounts		6,200,000
Funds designated for operational use		$ 2,000,000
Over-Allotment Option
Organization and Financing
Sale of units	1,000,000
Over-Allotment Option and Private Placement
Organization and Financing
Payment of underwriting discounts	$ 200,000
Over-Allotment Option and Private Placement \| Assets held in trust
Organization and Financing
Net proceeds from sale of units	$ 10,000,000

Organization and Plan of Business Operations - The Trust Account (Details)	Jun. 30, 2018 USD ($)
U.S. Treasury bills \| Fair Value, Inputs, Level 1
The Trust Account
Cash and cash equivalents held in the Trust Account	$ 314,820,605

Commitments (Details) - item	Jun. 30, 2018	Oct. 14, 2016
Registration Rights
Maximum number of demands	3
IPO
Underwriting Agreement
Underwriting discount		2.00%
Deferred underwriting discount	3.50%
Over-Allotment Option
Underwriting Agreement
Underwriting discount		2.00%
Deferred underwriting discount	3.50%

Cash Held in Trust Account (Details)	Oct. 14, 2016 USD ($)
IPO and Over-Allotment Option
Cash Held in Trust Account
Gross proceeds from sale of units	$ 310,000,000
Private Placement
Cash Held in Trust Account
Proceeds from issuance of Private Placement Warrants	8,200,000
IPO
Cash Held in Trust Account
Gross proceeds from sale of units	310,000,000
Underwriting discounts	6,200,000
Funds designated for operational use	$ 2,000,000